Page 1

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress tools.eurolandir.com/tools/Pressreleases/GetPress Release / - Completed 78 - week follow - up for hemophilia B pivotal study , with top - line data expected by year - end 2021 ~ ~ Enrolled 14 patients to date in Phase 1/2 clinical trial of AMT - 130 in Huntington's Disease , with no significant safety concerns observed ~ Preliminary data on first four patients in ongoing Phase I / II clinical trial of AMT - 130 and initiation of European Phase Ib / ll clinical trial expected by year - end 2021 ~ - Closed acquisition of Corlieve Therapeutics adding preclinical program in temporal lobe epilepsy to proprietary research pipeline ~ LEXINGTON , Mass . and AMSTERDAM , The Netherlands , Oct. 25 , 2021 ( GLOBE NEWSWIRE ) - uniQure N.V. ( NASDAQ : QURE ) , a leading gene therapy company advancing transformative therapies for patients with severe medical needs , today reported its financial results for the third quarter of 2021 and highlighted recent progress across its business . " We continue to make strong progress across our clinical trials and research programs , and CSL Behring is making significant strides towards a BLA submission for etranacogene dezaparvovec in hemophilia B , which is expected in the first half of 2022 , " stated Matt Kapusta , chief executive officer at uniQure . " Before the end of this year , we look forward to announcing clinical data from our Huntington's disease gene therapy program , including preliminary data on the first four patients in our ongoing U.S. Phase I / II study of AMT - 130 . Additionally , top - line 78 - week follow - up data on all HOPE - B pivotal study patients is expected to be announced by CSL Behring in late 4Q2021 . " 1/9